Soleno Therapeutics, Inc. or Novavax, Inc.: Who Manages SG&A Costs Better?

Who Manages SG&A Costs Better: Soleno Therapeutics or Novavax?

In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Novavax, Inc. and Soleno Therapeutics, Inc. have shown contrasting approaches to SG&A management. From 2014 to 2023, Novavax's SG&A expenses surged by over 2,200%, peaking in 2022. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Soleno Therapeutics maintained a more conservative growth in SG&A costs, with a modest increase of around 360% over the same period. This suggests a more controlled and efficient cost management strategy. While Novavax's approach may indicate a robust growth strategy, Soleno's restraint could imply a focus on operational efficiency. Investors and stakeholders should consider these trends when evaluating the financial strategies of these companies.